ECSP045360A - Pirimidinas arilo sustituidas y el uso de estas - Google Patents

Pirimidinas arilo sustituidas y el uso de estas

Info

Publication number
ECSP045360A
ECSP045360A EC2004005360A ECSP045360A ECSP045360A EC SP045360 A ECSP045360 A EC SP045360A EC 2004005360 A EC2004005360 A EC 2004005360A EC SP045360 A ECSP045360 A EC SP045360A EC SP045360 A ECSP045360 A EC SP045360A
Authority
EC
Ecuador
Prior art keywords
treatment
prevention
formula
pirimidinas
compounds
Prior art date
Application number
EC2004005360A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045360A publication Critical patent/ECSP045360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención se relaciona con un método para tratar desórdenes responsables del bloqueo de los canales de Ion de sodio que utilizan compuestos de pirimidina aril sustituidos novedosos de fórmula I. O una sal farmacéuticamente aceptable, o solvato de esta, en donde A, R1, R2, R3 y R4 se definen en la descripción. La invención también se dirige al uso de los compuestos de la fórmula I para el tratamiento de daño neuronal luego de isquemia focal y global, para el tratamiento o prevención de condiciones neurodegenerativas tales como esclerosis lateral amiotrófica (ALS), y para el tratamiento, prevención o aminoración de dolor crónico o agudo, como agentes antitinnitus, como anticonvulsionantes, y como antimaniacos depresivos, como anestésicos locales, como antiarrítmicos y para el tratamiento o prevención de neuropatía diabética.
EC2004005360A 2002-03-13 2004-10-12 Pirimidinas arilo sustituidas y el uso de estas ECSP045360A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36354402P 2002-03-13 2002-03-13

Publications (1)

Publication Number Publication Date
ECSP045360A true ECSP045360A (es) 2005-01-03

Family

ID=27805282

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005360A ECSP045360A (es) 2002-03-13 2004-10-12 Pirimidinas arilo sustituidas y el uso de estas

Country Status (27)

Country Link
US (1) US7229993B2 (es)
EP (1) EP1483247B1 (es)
JP (1) JP4473583B2 (es)
KR (1) KR20040099324A (es)
CN (1) CN1646500A (es)
AP (1) AP2004003152A0 (es)
AT (1) ATE434610T1 (es)
AU (1) AU2003223049A1 (es)
BR (1) BR0308451A (es)
CA (1) CA2479036A1 (es)
CO (1) CO5611139A2 (es)
CR (1) CR7526A (es)
CY (1) CY1109355T1 (es)
DE (1) DE60328087D1 (es)
DK (1) DK1483247T3 (es)
EA (1) EA200401120A1 (es)
EC (1) ECSP045360A (es)
ES (1) ES2328471T3 (es)
IL (1) IL163940A0 (es)
IS (1) IS7468A (es)
MA (1) MA27196A1 (es)
MX (1) MXPA04008901A (es)
NO (1) NO20044311L (es)
PT (1) PT1483247E (es)
SI (1) SI1483247T1 (es)
TN (1) TNSN04174A1 (es)
WO (1) WO2003076414A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008398A1 (en) * 2001-07-16 2003-01-30 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AU2003257033A1 (en) * 2002-07-31 2004-02-16 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
EP1608317B1 (en) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2562244A1 (en) * 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP1917017B1 (en) * 2005-03-04 2010-02-03 Alsgen, Inc. Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues
JP5027137B2 (ja) 2005-09-14 2012-09-19 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤の投与
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
MX2013003101A (es) 2010-09-17 2013-09-26 Purdue Pharma Lp Compuestos de piridina y sus usos.
ES2540562T3 (es) 2010-10-05 2015-07-10 Purdue Pharma L.P. Compuestos de quinazolina como bloqueadores de canales de sodio
EP2655330B1 (en) 2010-12-22 2016-02-10 Purdue Pharma LP Substituted pyridines as sodium channel blockers
JP5941546B2 (ja) 2011-09-02 2016-06-29 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリミジン
WO2013064883A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9388137B2 (en) 2011-10-31 2016-07-12 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
JP6110516B2 (ja) 2013-03-04 2017-04-05 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリミジンカルボキサミド
US9493449B2 (en) 2013-03-15 2016-11-15 Purdue Pharma L.P. Carboxamide derivatives and use thereof
CA2922567A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
EP3083606B1 (en) 2013-12-20 2020-10-28 Purdue Pharma LP Pyrimidines and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3087059B1 (en) 2013-12-23 2020-04-29 Purdue Pharma L.P. Indazoles and use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
EP3097078B1 (en) 2014-01-24 2022-05-25 Purdue Pharma LP Pyridines and pyrimidines and use thereof
JP6556154B2 (ja) 2014-02-12 2019-08-07 パーデュー、ファーマ、リミテッド、パートナーシップ イソキノリン誘導体及びその使用
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
JP6386088B2 (ja) 2014-05-06 2018-09-05 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体及びその使用
CA2952124A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
US10202382B2 (en) 2014-06-13 2019-02-12 Purdue Pharma L.P. Azamorphinan derivatives and use thereof
MX2017010682A (es) 2015-02-19 2018-04-24 Purdue Pharma Lp Metodos y composiciones para disminuir el vaciado gastrico.
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1122533B (de) 1959-04-18 1962-01-25 Knoll Ag Chemischer Fabriken Verfahren zur Herstellung basisch substituierter 4-Amino-6-hydroxypyrimidine
MA18829A1 (fr) 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
US4492792A (en) * 1982-02-04 1985-01-08 Ube Industries, Ltd. Process for preparing 4-amino-5-dialkoxy-methylpyrimidine derivatives
GB8909560D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Chemical compounds
KR930702312A (ko) * 1990-08-31 1993-09-08 아만 히데아키 피리미딘 유도체 및 의약
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0558997A (ja) 1991-09-04 1993-03-09 Mitsubishi Kasei Corp チオカルバモイルアセトニトリル誘導体
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
KR950703539A (ko) 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
CA2147275A1 (en) 1992-10-16 1994-04-28 Hirokazu Yamada Pyrimidine derivative
WO1994026721A1 (fr) 1993-05-13 1994-11-24 Nkk Corporation Derive de pyrimidine et composition pharmaceutique
GB2281295A (en) * 1993-08-26 1995-03-01 Zeneca Ltd (2-Fluoroethyl) thio-substituted pyrimidines as nematicides
US5569655A (en) * 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5744492A (en) * 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
WO1995011235A1 (en) 1993-10-20 1995-04-27 The Upjohn Company Pyrimidinones as antiarthritic and anti-inflammatories
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
HUP0103836A3 (en) 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
JP4832647B2 (ja) * 1999-03-26 2011-12-07 ユーロ−セルティック エス． ア． アリール置換ピラゾール、イミダゾール、オキサゾール、チアゾールおよびピロール、ならびにそれらの使用
CO5210940A1 (es) 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen
AU6621600A (en) 1999-08-04 2001-03-05 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
DE19948434A1 (de) * 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
KR100840727B1 (ko) 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
HK1056164B (en) * 2000-03-24 2013-06-21 Euro-Celtique S.A. Aryl-substituted pyrazole, triazole and tetrazole, and their uses
AU4961001A (en) * 2000-03-31 2001-10-15 Cocensys Inc Aminopyridines and their use as anticonvulsants and sodium channel blockers
WO2003008398A1 (en) * 2001-07-16 2003-01-30 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
AR036873A1 (es) * 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento

Also Published As

Publication number Publication date
PT1483247E (pt) 2009-08-18
DE60328087D1 (de) 2009-08-06
MA27196A1 (fr) 2005-01-03
IL163940A0 (en) 2005-12-18
JP2005526069A (ja) 2005-09-02
US20030236273A1 (en) 2003-12-25
EP1483247B1 (en) 2009-06-24
MXPA04008901A (es) 2004-11-26
CR7526A (es) 2008-08-12
NO20044311L (no) 2004-12-10
DK1483247T3 (da) 2009-08-17
WO2003076414A2 (en) 2003-09-18
US7229993B2 (en) 2007-06-12
AU2003223049A1 (en) 2003-09-22
EA200401120A1 (ru) 2005-02-24
CN1646500A (zh) 2005-07-27
CO5611139A2 (es) 2006-02-28
ES2328471T3 (es) 2009-11-13
SI1483247T1 (sl) 2009-12-31
AP2004003152A0 (en) 2004-12-31
CA2479036A1 (en) 2003-09-18
EP1483247A2 (en) 2004-12-08
TNSN04174A1 (en) 2007-03-12
WO2003076414A3 (en) 2003-12-24
ATE434610T1 (de) 2009-07-15
CY1109355T1 (el) 2014-07-02
BR0308451A (pt) 2005-01-11
JP4473583B2 (ja) 2010-06-02
IS7468A (is) 2004-09-24
KR20040099324A (ko) 2004-11-26

Similar Documents

Publication Publication Date Title
ECSP045360A (es) Pirimidinas arilo sustituidas y el uso de estas
EA200500289A1 (ru) Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
BR0109706A (pt) Aminopiridinas e seus usos como anticonvulsivantes e bloqueadores dos canais de sódio
UY40234A (es) Compuestos heteroarilo para el tratamiento del dolor
CO2023017899A2 (es) N-(hidroxialquil(hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
MXPA05001288A (es) Compuestos benzoheterociclicos 2-biciclico sustituidos y sus uso como bloqueadores del canal de sodio.
AR023171A1 (es) Pirazoles, imidazoles, oxazoles, tiazoles, y pirroles sustituidos por arilo, y el uso de los mismos.
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
MX390793B (es) Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio.
ECSP078003A (es) Inhibidores de aspartil proteasas
CR6774A (es) Sustitutos arilicos de piridinas, pirimidinas, pirazinas, triazinas y el uso de estos
EA200300172A1 (ru) Метод обезболивания
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
UY28514A1 (es) Nuevos compuestos
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
ES2154318T3 (es) Agentes antitromboticos.
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
MXPA05001293A (es) Compuestos aril aminoalquilo-sustituidos y su uso como bloqueadores del canal de sodio.
CO4480740A1 (es) Polimorfos del profarmaco de 6-n-(l-ala-l-ala)-trovafloxaci- na
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
AR056720A1 (es) Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
AR057300A1 (es) Estirilsulfonamidas, su obtencion y uso como agentes farmaceuticos